Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits

British Journal of Pharmacology

Volumn 119, Issue 2, 1996, Pages 365-373

  Tomoda, Fumihiro ^a,b   Lew, Rebecca A ^a   Smith, A Ian ^a   Madden, Anna C ^a   Evans, Roger G ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF TOYAMA   (Japan)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin converting enzyme; Bradykinin; Conscious rabbit; Hoe 140; Metalloendopeptidase 24.11; Metalloendopeptidase 24.15; Renal function

Indexed keywords

4 AMINOBENZOIC ACID DERIVATIVE; BRADYKININ; BRADYKININ B2 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; ICATIBANT; MEMBRANE METALLOENDOPEPTIDASE; N (1 CARBOXY 3 PHENYLPROPYL)ALANYLALANYLTYROSYL 4 AMINOBENZOATE; N (1 CARBOXY 3 PHENYLPROPYL)PHENYLALANYLISOSERINE; PROTEINASE; SODIUM ION; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSOR RESPONSE; DRUG EFFECT; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HEART RATE; HEART RIGHT ATRIUM; HEMODYNAMICS; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; MICTURITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RABBIT; SODIUM EXCRETION;

EID: 0029793682     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15995.x     Document Type: Article

References (46)

1. 8. J. Neurochem., 48, 284-292.
2. ADER, J.L., PRADDAUDE, F., TRAN-VAN, T., EMOND, C., TACK, I., REGOLI, D. & GIROLAMI, J.P. (1992). Direct effects of bradykinin on glomerular filtration and proximal tubule reabsorption in rat kidney. Recent Prog. Kinins., 38, 128-133.
3. AUSTRALIAN CODE OF PRACTICE FOR THE CARE AND USE OF ANIMALS FOR SCIENTIFIC PURPOSES. (1990). Canberra. Australia: Australian Government Publishing Service.
4. BARELLI, H., FOX-THRELKELD, J.E.T., DIVE, V., DANIEL, E.E., VINCENT, J.P. & CHECLER, F. (1994). Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum. Br. J. Pharmacol., 112, 127-132.
5. 2 receptor antagonism on the hypotensive effects of ACE inhibition. Br. J. Pharmacol., 113, 717-722.
6. CARDOZO, C. & ORLOWSKI, M. (1993). Evidence that enzymatic conversion of N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, a specific inhibitor of endopeptidase 24.15, to N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala is necessary for inhibition of angiotensin converting enzyme. Peptides, 14, 1259-1262.
7. CHAPPELL, M.C., WELCHES, W.R., BROSNIHAN, K.B. & FERRARI, C.M. (1992). Inhibition of angiotensin converting enzyme by the metalloendopeptidase 3.4.24.15 inhibitor c-phenylpropyl-alanyl-alanyl-phenylalanyl-p-aminobenzoate. Peptides, 13, 943-946.
8. CHEN, K. & ZIMMERMAN, B.G. (1994). Comparison of renal hemodynamic effect of ramiprilat to captopril; possible role of kinins. J. Pharmacol. Exp. Ther., 270, 491-497.
9. CHU, T.G. & ORLOWSKI, M. (1984). Active site directed N-carboxymethyl peptide inhibitors of a soluble metalloendopeptidase from rat brain. Biochemistry, 23, 3598-3603.
10. CHU, T.G. & ORLOWSKI, M. (1985). Soluble metalloendopeptidase from rat brain: action on enkephalin-containing peptides and other bioactive peptides. Endocrinology, 116, 1418-1425.
11. 2-adrenoceptors. Br. J. Pharmacol., 116, 1557-1570.
12. EVANS, R.G., RANKIN, A.J. & ANDERSON, W.P. (1994). Interactions of blockade of nitric oxide synthase and angiotensin-converting enzyme on renal function in conscious rabbits. J. Cardiovasc. Pharmacol., 24, 542-551.
13. 2 receptor antagonist. Hoe 140, in isolated blood vessels from different species. Br. J. Pharmacol., 112, 683-689.
14. FIGUEROA, C.D., GONZALEZ, C.B., GRIGORIEV, S., ABD ALLA, S., HAASEMANN, M., JARNAGIN, K. & MÜLLER-ESTERL, W. (1995). Probing for the bradykinin B2 receptor in rat kidney by anti-peptide and anti-ligand antibodies. J. Histochem. Cytochem., 43, 137-148.
15. FRENCH, J.F., ANDERSON, B.A., DOWNS, T.R. & DAGE, R.C. (1995). Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J. Cardiovasc. Pharmacol., 26, 107-113.
16. HARTMAN, J.C., WALL, T.M., HULLINGER, T.G. & SHEBUSKI, R.J. (1993). Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist Hoe 140. J. Cardiovasc, Pharmacol., 21, 996-1003.
17. KON, V., FOGO, A. & ICHIKAWA, I. (1993). Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int., 44, 545-550.
18. KOOMANS, H.A., BOER, W.H. & DORHOUT MEES, E.J. (1989). Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int., 36, 2-12.
19. LASDUN, A. & ORLOWSKI, M. (1990). Inhibition of endopeptidase 24.15 greatly increases the release of luteinizing hormone and follicle stimulating hormone in response to luteinizing hormone/ releasing hormone. J. Pharmacol. Exp. Ther., 253, 1265-1271.
20. LASDUN, A., REZNIK, S., MOLINEAUX, C.J. & ORLOWSKI, M. (1989). Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone. J. Pharmacol. Exp. Ther., 251, 439-447.
21. LEW, R.A., TETAZ, T.J., GLUCKSMAN, M.J., ROBERTS, J.L. & SMITH, A.I. (1994). Evidence for a two-step mechanism of gonadotropin-releasing hormone metabolism by prolyl endopeptidase and metalloendopeptidase EC 3.4.24.15 in ovine hypothalamic extracts. J. Biol. Chem., 269, 12626-12632.
22. LEW, R.A., TOMODA, F., EVANS, R.G., LAKAT, L., BOUBLIK, J.H., PIPOLO, L.A. & SMITH, A.I. (1996). Synthetic inhibitors of endopeptidase EC3.4.24.15: potency and stability in vitro and in vivo. Br. J. Pharmacol., 118, (in press).
23. LUDBROOK, J. (1991). On making multiple comparisons in clinical and experimental pharmacology and physiology. Clin. Exp. Pharmacol. Physiol., 18, 379-392.
24. LUDBROOK, J. (1994). Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res., 28, 303-311.
25. MAJIMA, M. & KATORI, M. (1995). Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. Trends Pharmacol. Sci., 16, 239-246.
26. MOTWANI, J.G., LANG, C.C., CRAMB, G. & STRUTHERS, A.D. (1995). Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men. Hypertension, 25, 637-642.
27. ORLOWSKI, M., MICHAUD, C. & CHU, T.G. (1983). A soluble metalloendopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Eur. J. Biochem., 135, 81-88.
28. ORLOWSKI, M., MICHAUD, C. & MOLINEAUX, C.J. (1988). Substrate-related potent inhibitors of brain metallo-endopeptidase. Biochemistry, 27, 597-602.
29. ORLOWSKI, M., REZNIK, S., AYALA, J. & PIEROTTI, A.R. (1989). Endopeptidase 24.15 from rat testes. Isolation of the enzyme and its specificity toward synthetic and natural peptides, including enkephalin-containing peptides. Biochem. J., 261, 951-958.
30. PHAM, I., GONZALEZ, W., EL AMRANI, A.-I.K., FOURNIE-ZALUSKI, M.-C., LABOULANDINE, I., ROQUES, B.P. & MICHEL, J.-B. (1993). Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J. Pharmacol. Exp. Ther., 265, 1339-1347.
31. 8] bradykinin). Eur. J. Pharmacol., 210, 115-120.
32. 2, water, and sodium excretion. Hypertension, 25, 1008-1013.
33. SEYMOUR, A.A., ASAAD, M.M., LANOCE, V.M., LANGENBACHER, K.M., FENNELL, S.A. & ROGERS, W.L. (1993). Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J. Pharmacol. Exp. Ther., 266, 872-883.
34. SEYMOUR, A.A., SHELDON, J.H., SMITH, P.L., ASAAD, M. & ROGERS, W.L. (1994). Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anaesthetised dogs. J. Pharmacol. Exp. Ther., 269, 263-270.
35. SMITH, H.W., FINKELSTEIN, N., ALIMINOSA, L., CRAWFORD, B. & GRABER, M. (1945). The renal clearance of substituted hippuric acid derivatives and other aromatic acids in dog and man. J. Clin. Invest., 24, 388-404.
36. SYBERTZ, E.J., CHIU, P.J.S., VEMULAPALLI, S., PITTS, B., FOSTER, C.J., WATKINS, R.W., BARNETT, A. & HASLANGER, M.F. (1989). SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J. Pharmacol. Exp. Ther., 250, 624-631.
37. TELFORD, S.E., SMITH, A.I., LEW, R.A. PERICH, R.B., MADDEN, A.C. & EVANS, R.G. (1995). Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor. Br. J. Pharmacol., 114, 1185-1192.
38. TOMODA, F., LEW, R.A., SMITH, A.I. & EVANS, R.G. (1995). The endopeptidase 24.11 inhibitor SCH 39370 does not prevent conversion of N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Tyr-p-aminobenzoate to an angiotensin converting enzyme inhibitor in vivo. Proc. Aus. Physiol. Pharmacol. Soc., 26, 75P (Abstract).
39. URA, N., SHIMAMOTO, K., KURODA, S., NOMURA, N., IWATA, M., AOYAMA, T. & IIMURA, O. (1994). The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats. Clin. Exp. Hyperten., 16, 799-808.
40. VERA, W.O., FOURNIÉ-ZALUSKI, M.-C., PHAM, I., LABOULANDINE, I., ROQUES, B.-P. & MICHEL, J-B. (1995). Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J. Pharmacol. Exp. Ther., 272, 343-351.
41. VINCENT, B., DIVE, V., YIOTAKIS, A., SMADJA, C., MALDONADO, R., VINCENT, J.-P. & CHECLER, F. (1995). Phosphorus-containing peptides as mixed inhibitors of endopeptidase 3.4.24.15 and 3.4.24.16: effect on neurotensin degradation in vitro and in vivo. Br. J. Pharmacol., 115, 1053-1063.
42. WILLIAMS, C.H., YAMAMOTO, T., WALSH, D.M. & ALLSOP, D (1993). Endopeptidase 3.4.24.11 converts N-1-(R,S)carboxy-3-phenylpropyl-Ala-Ala-Phe-p-carboxyanilide into a potent inhibitor of angiotensin-converting enzyme. Biochem. J., 294, 681-684.
43. WILKINSON, L. (1990). SYSTAT: The System for Statistics. Evanston, IL: SYSTAT Inc.
44. WILLIS, L.R., LUDENS, J.H., HOOK, J.B. & WILLIAMSON, H.E. (1969). Mechanism of natriuretic action of bradykinin. Am. J. Physiol., 217, 1-5.
45. WIRTH, K., HOCK, F.J., ALBUS, U., LINZ, W., ALPERMANN, H.G., ANAGNOSTOPOULOS, H., HENKE, ST., BREIPOHL, G., KÖNIG, W., KNOLLE, J. & SCHÖLKENS, B. A. (1991). Hoe 140 a potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol., 102, 774-777.
46. YANG, X.-P., SAITOH, S., SCICLI, A.G., MASCHA, E., ORLOWSKI, M. & CARRETERO, O.A. (1994). Effects of a metalloendopeptidase-24.15 inhibitor on renal hemodynamics and function in rats. Hypertension, 23 (suppl. 1), I-235-I-239.